Adaptimmune gets FDA designation to accelerate development of cancer therapy

The Food and Drug Administration has awarded a key designation to a therapy Adaptimmune is developing for a rare type of cancer. Adaptimmune's experimental T-cell therapy, called ADP-A2M4, targets synovial sarcoma, a cancer that occurs primarily in the extremities of the arms or legs. About two people out of every one million are diagnosed with the condition annually. The FDA designated ADP-42M4 as a regenerative medicine advanced therapy. That designation, established as part of the 21st Century…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news